

# Recbio (2179 HK)

## Superior immunogenicity on ReCOV vs. Pfizer's mRNA vaccine

Recbio announced positive results in the Phase II study of its COVID vaccine ReCOV which compared the immunogenicity and safety to Pfizer's mRNA vaccine, COMIRNATY®, as a booster vaccination. The head-to-head trial enrolled 600 subjects with basic immunization of two doses of inactive vaccines in the Philippines and the results were upon 14 days post-booster.

- Statistical superiority in immunogenicity vs. COMIRNATY® against both prototype strains and Omicron strains.** In live neutralization assays against prototype strains, the seroconversion rate (SCR) neutralizing antibody strain of the ReCOV group and COMIRNATY® group was 96.0% vs. 91.0%, P value=0.039. The GMT in the ReCOV group was significantly higher than that in the mRNA vaccine group (7,781.8 vs. 5,605.3, P value<0.001). Neutralizing antibody level induced by ReCOV increased by 25.1 times compared with the baseline, which was higher than that of the mRNA vaccine (15.7 times). In live neutralization assays against Omicron BA.2 and BA.5, the GMTs in the ReCOV group (5687 and 4387.4, respectively) were both significantly higher than that in the mRNA vaccine group (3997.2 and 3100.6, respectively) (P value<0.001). The superior immunogenicity was shown in both adults and elderly sub-groups.
- Excellent cross-neutralization effect.** In the previous study, the neutralizing antibody titer was lower by 7.0 against BA.2 and 21.0 against BA.4/5 two weeks after homologous booster vaccination of Pfizer's mRNA vaccines ([Link](#)). However, the neutralizing antibodies induced by ReCOV against BA.2 and BA.5 were only 1.37 and 1.77 times lower than that against prototype strains, indicating ReCOV's broad neutralization.
- Good safety profile.** As of the data analysis date, no SAE and TEAE leading to early discontinuation were reported. The majority of TEAEs were grade 1 to grade 2 in severity and recovered in a short time. Most common solicited systemic TEAEs included headache, fever and myalgia. The incidence of TEAE was similar in the adult and elderly sub-groups, which supported ReCOV to be used for the elderly as officials calling on the elderly to get basic and first/second doses of booster vaccinated.
- IND application approved by FDA of the Philippines for REC610.** Recbio has received approval to conduct Phase I trial of its recombinant shingles vaccine, REC610, in the Philippines, evaluating the safety and immunogenicity of REC610 vs. GSK Shingrix®. Additionally, Recbio expanded the vaccine's indication to adult aged 40 and above, compared to Shingrix® which indicated for adults aged 50 and older.
- Maintain BUY.** We expect Recbio to receive EUA/ BLA for ReCOV in 2023E and submit BLA of REC610 to the NMPA in 2024E. We revised our TP to HK\$38.86 (WACC: 11.2%, terminal growth rate: 2.5%).

### Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	0	0	0	146	487
YoY growth (%)	na	na	na	na	234.3
Net profit (RMB mn)	(179)	(658)	(668)	(741)	(726)
EPS (Reported) (RMB cents)	na	na	(138.30)	(153.46)	(150.27)
R&D expenses (RMB)	(131)	(473)	(500)	(500)	(500)
Admin expenses (RMB mn)	(18)	(143)	(180)	(198)	(218)
CAPEX (RMB mn)	(138)	(238)	(300)	(300)	(250)

Source: Company data, Bloomberg, CMBIGM estimates

**BUY (Maintain)**

**Target Price** HK\$38.86  
 (Previous TP) HK\$38.77  
**Up/Downside** 72.33%  
**Current Price** HK\$22.55

### China Healthcare

**Jill WU, CFA**  
 (852) 3900 0842  
 jillwu@cmbi.com.hk

**Cathy WANG**  
 (852) 3916 1729  
 cathywang@cmbi.com.hk

### Stock Data

Mkt Cap (HK\$ mn)	10,891
Avg 3 mths t/o (HK\$ mn)	4.84
52w High/Low (HK\$)	28.30/ 17.72
Total Issued Shares (mn)	94

Source: Bloomberg

### Shareholding Structure

Management	17.3%
Legend Capital	10.0%


Source: HKEx

### Share Performance

	Absolute	Relative
1-mth	14.2%	5.6%
3-mth	8.4%	4.6%
6-mth	11.5%	20.8%

Source: Bloomberg

### 12-mth Price Performance



Source: Bloomberg

### Related report:

- Recbio Technology (2179 HK) – Smooth progress of core pipeline products – 29 Aug 2022

**Figure 1: CMBIGM earnings revisions**

(RMB mn)	New			Old			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	0	146	487	62	1,745	1,446	N/A	-91.6%	-66.3%
Gross profit	0	29	112	40	1,151	969	N/A	-97.5%	-88.4%
Operating profit	-664	-712	-652	-781	-210	-200	N/A	N/A	N/A
Net profit	-668	-741	-726	-785	-239	-266	N/A	N/A	N/A
EPS (RMB cents)	-1.38	-1.53	-2	-1.63	-0.49	-1	N/A	N/A	N/A
Gross margin	N/A	20.00%	23.00%	64.52%	65.96%	67.01%	N/A	-45.96 ppt	-44.01 ppt

Source: Company data, CMBIGM estimates

**Figure 2: CMBIGM estimates vs consensus**

(RMB mn)	CMBIGM			Consensus			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	0	146	487	131	1,754	1,577	N/A	-91.7%	-69.1%
Gross Profit	0	29	112	82	1,343	1213	N/A	-97.8%	-90.8%
Operating Profit	-664	-712	-652	-781	124	160	N/A	N/A	N/A
Net profit	-668	-741	-726	-744	111	127	N/A	N/A	N/A
EPS (RMB cents)	-1	-2	-2	-1.52	0.41	0.46	N/A	N/A	N/A
Gross Margin	N/A	20.00%	23.00%	62.50%	76.57%	76.90%	N/A	-56.6 ppt	-53.9 ppt

Source: Company data, CMBIGM estimates

## Valuation

**Figure 3: Risk-adjusted DCF valuation**

DCF Valuation (in Rmb mn)	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	-679	-724	-661	-599	281	1,415	2,298	3,123	3,761	4,310	4,783	5,331	5,427	5,399
Tax rate	0.0%	0.0%	0.0%	0.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%
EBIT*(1-tax rate)	-679	-724	-661	-599	238	1,203	1,953	2,655	3,197	3,664	4,066	4,532	4,613	4,589
+ D&A	29	38	45	52	57	61	62	63	65	66	67	68	69	70
- Change in working capital	-108	-71	-160	-130	-538	-1,427	-1,177	-964	-771	-705	-653	-757	-132	38
- Capex	-300	-300	-250	-250	-200	-200	-100	-100	-100	-100	-100	-100	-100	-100
FCFF	-1,058	-1,057	-1,026	-928	-443	-363	738	1,654	2,391	2,924	3,379	3,742	4,450	4,597
Terminal value														53,984
Terminal growth rate	2.5%													
WACC	11.2%													
Cost of Equity	14.0%													
Cost of Debt	5.6%													
Equity Beta	1.10													
Risk Free Rate	3.0%													
Market Risk Premium	10.0%													
Target Debt to Asset ratio	30.0%													
Effective Corporate Tax Rate	15.0%													
Terminal value	12,169													
Total PV	15,787													
Net debt	-729													
Minority interest	-0													
Equity value (RMB mn)	16,516													
Equity value (HK\$ mn)	483													
No. of shares outstanding (mn)	34.20													
DCF per share (HK\$)	38.86													

Source: CMBIGM estimates

**Figure 4: Sensitivity analysis (HK\$)**

		WACC				
		10.2%	10.7%	11.2%	11.7%	12.2%
Terminal growth rate	3.5%	54.36	48.17	42.88	38.32	34.35
	3.0%	51.22	45.60	40.75	36.53	32.85
	2.5%	48.49	43.34	38.86	34.95	31.50
	2.0%	46.10	41.34	37.18	33.52	30.29
	1.5%	43.97	39.55	35.67	32.24	29.19

Source: CMBIGM estimates

## Financial Summary

INCOME STATEMENT	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec (RMB mn)						
Revenue	0	0	0	0	146	487
Cost of goods sold	0	0	0	0	(117)	(375)
Gross profit	0	0	0	0	29	112
Selling expense	0	0	(3)	(4)	(60)	(60)
Admin expense	(12)	(18)	(143)	(180)	(198)	(218)
R&D expense	(63)	(131)	(473)	(500)	(500)	(500)
Others	(76)	(37)	(56)	(4)	(29)	(74)
Operating profit	(62)	(142)	(601)	(664)	(712)	(652)
Other income	13	10	28	20	17	14
Other expense	0	(3)	(10)	0	0	0
Pre-tax profit	(138)	(179)	(658)	(668)	(741)	(726)
Income tax	0	0	0	0	0	0
After tax profit	(138)	(179)	(658)	(668)	(741)	(726)
Minority interest	0	0	(0)	0	0	0
Net profit to shareholders	(138)	(179)	(658)	(668)	(741)	(726)

BALANCE SHEET	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec (RMB mn)						
Current assets	311	709	1,295	894	974	1,028
Cash & equivalents	57	356	1,183	806	732	441
Account receivables	0	0	0	0	60	200
Inventories	7	8	24	0	94	298
Prepayment	14	20	88	88	88	88
Financial assets at FVTPL	232	326	0	0	0	0
Non-current assets	116	338	625	895	1,157	1,362
PP&E	56	129	416	692	959	1,168
Intangibles	22	22	22	22	22	22
Goodwill	9	9	9	9	9	9
Other non-current assets	28	178	177	172	167	163
Total assets	427	1,047	1,919	1,790	2,132	2,390
Current liabilities	18	57	139	8	91	275
Account payables	2	2	17	0	58	185
Other current liabilities	16	55	122	8	33	90
Non-current liabilities	728	1,998	107	107	1,107	1,907
Long-term borrowings	0	0	50	50	1,050	1,850
Deferred income	0	18	32	32	32	32
Other non-current liabilities	728	1,980	24	24	24	24
Total liabilities	746	2,056	246	114	1,198	2,182
Share capital	0	0	448	448	448	448
Total shareholders equity	(320)	(1,009)	1,673	1,675	934	208
Minority interest	0	0	(0)	(0)	(0)	(0)
Total equity and liabilities	427	1,047	1,919	1,790	2,132	2,390

<b>CASH FLOW</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec (RMB mn)</b>						
<b>Operating</b>						
Profit before taxation	(138)	(179)	(658)	(668)	(741)	(726)
Depreciation & amortization	4	13	22	29	38	45
Tax paid	0	0	0	0	0	0
Change in working capital	(68)	64	(19)	(108)	(71)	(160)
Others	64	32	181	(11)	17	65
<b>Net cash from operations</b>	<b>(139)</b>	<b>(70)</b>	<b>(473)</b>	<b>(758)</b>	<b>(757)</b>	<b>(776)</b>
<b>Investing</b>						
Capital expenditure	(79)	(138)	(238)	(300)	(300)	(250)
Acquisition of subsidiaries/ investments	2	0	0	0	0	0
Others	(269)	(120)	307	15	12	9
<b>Net cash from investing</b>	<b>(346)</b>	<b>(259)</b>	<b>69</b>	<b>(285)</b>	<b>(288)</b>	<b>(241)</b>
<b>Financing</b>						
Dividend paid	0	0	0	0	0	0
Net borrowings	0	0	50	0	1,000	800
Proceeds from share issues	0	0	0	670	0	0
Others	490	680	1,179	(4)	(29)	(74)
<b>Net cash from financing</b>	<b>490</b>	<b>680</b>	<b>1,229</b>	<b>666</b>	<b>971</b>	<b>726</b>
<b>Net change in cash</b>						
Cash at the beginning of the year	1	7	356	1,183	806	732
Exchange difference	0	(3)	(8)	0	0	0
<b>Cash at the end of the year</b>	<b>7</b>	<b>356</b>	<b>1,173</b>	<b>806</b>	<b>732</b>	<b>441</b>
<b>GROWTH</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec</b>						
Revenue	na	na	na	na	na	234.3%
Gross profit	na	na	na	na	na	284.5%
<b>PROFITABILITY</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec</b>						
Gross profit margin	na	na	na	na	20.0%	23.0%
Operating margin	na	na	na	na	(488.5%)	(133.7%)
Return on equity (ROE)	na	na	(197.9%)	(39.9%)	(56.8%)	(127.1%)
<b>GEARING/LIQUIDITY/ACTIVITIES</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec</b>						
Current ratio (x)	17.5	12.3	9.3	113.7	10.7	3.7
Receivable turnover days	na	na	na	150.0	150.0	150.0
Inventory turnover days	na	na	na	300.0	295.0	290.0
Payable turnover days	na	na	na	180.0	180.0	180.0
<b>VALUATION</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec</b>						
Div yield (%)	na	na	na	0.0	0.0	0.0

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

## CMBIGM Ratings

<b>BUY</b>	: Stock with potential return of over 15% over next 12 months
<b>HOLD</b>	: Stock with potential return of +15% to -10% over next 12 months
<b>SELL</b>	: Stock with potential loss of over 10% over next 12 months
<b>NOT RATED</b>	: Stock is not rated by CMBIGM
<b>OUTPERFORM</b>	: Industry expected to outperform the relevant broad market benchmark over next 12 months
<b>MARKET-PERFORM</b>	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
<b>UNDERPERFORM</b>	: Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advice and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume a responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as at time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBIGMG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBIGMG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBIGMG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBIGMG at +65 6350 4400 for matters arising from, or in connection with the report.